Sign in or create an account to add this stock to your watchlist.
About Aerie Pharmaceuticals (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300
Debt
Debt-to-Equity Ratio0.52
Current Ratio13.57
Quick Ratio13.53
Price-To-Earnings
Trailing P/E Ratio-14.73
Forward P/E Ratio-13.24
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.98 per share
Price / Book8.30
Profitability
EPS (Most Recent Fiscal Year)($3.37)
Net Income$-145,100,000.00
Net MarginsN/A
Return on Equity-84.90%
Return on Assets-46.26%
Miscellaneous
Employees160
Outstanding Shares39,500,000
Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions
What is Aerie Pharmaceuticals' stock symbol?
Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."
How were Aerie Pharmaceuticals' earnings last quarter?
Aerie Pharmaceuticals (NASDAQ:AERI) released its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.04. View Aerie Pharmaceuticals' Earnings History.
What price target have analysts set for AERI?
10 equities research analysts have issued 1 year price objectives for Aerie Pharmaceuticals' shares. Their predictions range from $68.00 to $86.00. On average, they anticipate Aerie Pharmaceuticals' share price to reach $77.6667 in the next twelve months. View Analyst Ratings for Aerie Pharmaceuticals.
What are Wall Street analysts saying about Aerie Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
- 1. Canaccord Genuity analysts commented, "We continue to view Aerie positively, with catalysts for Roclatan, OUS geographies and additional clinical progression as potential inflection points that build on what will likely be solid acceptance of Rhopressa. We maintain our BUY rating and DCF-driven $86 PT on AERI shares." (5/15/2018)
- 2. Mizuho analysts commented, "We remain confident in the management team as the Rhopressa launch progresses and reiterate our Buy rating on the stock." (5/9/2018)
- 3. According to Zacks Investment Research, "Aerie received a significant boost with the recent approval of lead drug Rhopressa. The approval came ahead of the PDUFA date. Meanwhile, Aerie is also evaluating Roclatan, a once-daily, quadruple action fixed-dose combination of Rhopressa and Xalatan. Aerie’s shares have outperformed the industry in the last twelve months. However, Rhopressa faces stiff competition from established branded and generic pharmaceutical companies, such as Novartis’ Simbrinza and Travtan, and Allergan’s Lumigan, as well as other smaller biotechnology and pharmaceutical companies. Valeant Pharmaceutical’s Vyzulta is also approved for open-angle glaucoma or ocular hypertension. Rhopressa will face a tough time in gaining market share due to competition from these products. Any approval delays for Roclatan like Rhopressa will be detrimental to the company's growth prospects." (4/17/2018)
Who are some of Aerie Pharmaceuticals' key competitors?
Some companies that are related to Aerie Pharmaceuticals include Bio-Techne (TECH), CRISPR Therapeutics (CRSP), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI), Repligen (RGEN), Editas Medicine (EDIT), Acceleron Pharma (XLRN), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX) and Iovance Biotherapeutics (IOVA).
Who are Aerie Pharmaceuticals' key executives?
Aerie Pharmaceuticals' management team includes the folowing people:
- Dr. Vincente J. Anido Jr., Ph.D., Chairman & CEO (Age 65)
- Mr. Thomas A. Mitro, Pres & COO (Age 60)
- Mr. Richard James Rubino CPA, CFO & Sec. (Age 60)
- Dr. Casey C. Kopczynski Ph.D., Co-Founder & Chief Scientific Officer (Age 57)
- Ms. Jessica Crespo CPA, Director of Accounting
Has Aerie Pharmaceuticals been receiving favorable news coverage?
Media headlines about AERI stock have trended somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aerie Pharmaceuticals earned a daily sentiment score of 0.24 on Accern's scale. They also gave news headlines about the company an impact score of 47.10 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Aerie Pharmaceuticals' major shareholders?
Aerie Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.95%), Columbus Circle Investors (1.60%), Summit Trail Advisors LLC (1.11%), Northern Trust Corp (1.10%), Millennium Management LLC (0.98%) and Neuberger Berman Group LLC (0.81%). Company insiders that own Aerie Pharmaceuticals stock include Foresite Capital Fund Ii, LP, Geoffrey M Duyk and Gerald D Cagle. View Institutional Ownership Trends for Aerie Pharmaceuticals.
Which major investors are selling Aerie Pharmaceuticals stock?
AERI stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Barclays PLC, Russell Investments Group Ltd., Citigroup Inc., Suffolk Capital Management LLC, BlackRock Inc., Millennium Management LLC and Eversept Partners LLC. View Insider Buying and Selling for Aerie Pharmaceuticals.
Which major investors are buying Aerie Pharmaceuticals stock?
AERI stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Highland Capital Management LP, Handelsbanken Fonder AB, Handelsbanken Fonder AB, OppenheimerFunds Inc., Neuberger Berman Group LLC, PointState Capital LP and Columbus Circle Investors. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP and Gerald D Cagle. View Insider Buying and Selling for Aerie Pharmaceuticals.
How do I buy shares of Aerie Pharmaceuticals?
Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aerie Pharmaceuticals' stock price today?
One share of AERI stock can currently be purchased for approximately $49.65.
How big of a company is Aerie Pharmaceuticals?
Aerie Pharmaceuticals has a market capitalization of $1.97 billion. The company earns $-145,100,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Aerie Pharmaceuticals employs 160 workers across the globe.
How can I contact Aerie Pharmaceuticals?
Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]
MarketBeat Community Rating for Aerie Pharmaceuticals (AERI)
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aerie Pharmaceuticals (NASDAQ:AERI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Aerie Pharmaceuticals in the last 12 months. Their average twelve-month price target is $77.6667, suggesting that the stock has a possible upside of 56.43%. The high price target for AERI is $86.00 and the low price target for AERI is $68.00. There are currently 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.92 | 2.92 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $77.6667 | $79.9091 | $74.8462 | $71.8462 |
| Price Target Upside: | 56.43% upside | 47.30% upside | 39.51% upside | 20.35% upside |
Aerie Pharmaceuticals (NASDAQ:AERI) Consensus Price Target History
Aerie Pharmaceuticals (NASDAQ:AERI) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Aerie Pharmaceuticals (NASDAQ:AERI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aerie Pharmaceuticals (NASDAQ AERI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.53%
Aerie Pharmaceuticals (NASDAQ AERI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/25/2018 | Gerald D Cagle | Director | Buy | 1,000 | $49.45 | $49,450.00 | 16,050 |  |
| 5/21/2018 | Gerald D Cagle | Director | Buy | 1,000 | $50.25 | $50,250.00 | 15,050 | |
| 5/26/2017 | Foresite Capital Fund Ii, L.P. | Major Shareholder | Sell | 20,000 | $55.95 | $1,119,000.00 | | |
| 4/19/2017 | Gerald D Cagle | Director | Buy | 2,000 | $41.70 | $83,400.00 | 10,900 | |
| 2/15/2017 | Geoffrey M Duyk | Director | Sell | 41,591 | $46.63 | $1,939,388.33 | 10,067 | |
| 10/6/2016 | Foresite Capital Fund Ii, L.P. | Major Shareholder | Sell | 50,000 | $40.34 | $2,017,000.00 | | |
| 7/22/2016 | Foresite Capital Fund Ii, L.P. | Major Shareholder | Buy | 250,000 | $17.50 | $4,375,000.00 | | |
| 4/15/2015 | Anand Mehra | Director | Sell | 425,000 | $33.64 | $14,297,000.00 | | |
| 1/8/2015 | Lifesciences Ii L.P. Clarus | Major Shareholder | Sell | 175,000 | $31.11 | $5,444,250.00 | | |
| 1/5/2015 | Lifesciences Ii L.P. Clarus | Major Shareholder | Sell | 23,620 | $30.86 | $728,913.20 | | |
| 12/29/2014 | Lifesciences Ii L.P. Clarus | Major Shareholder | Sell | 80,724 | $30.05 | $2,425,756.20 | | |
| 12/23/2014 | Lifesciences Ii L.P. Clarus | Major Shareholder | Sell | 49,704 | $30.36 | $1,509,013.44 | | |
| 12/22/2014 | Lifesciences Ii L.P. Clarus | Major Shareholder | Sell | 49,441 | $30.36 | $1,501,028.76 | | |
| 11/25/2014 | Anand Mehra | Director | Sell | 800,000 | $26.00 | $20,800,000.00 | | |
| 11/25/2014 | Group Holdings (Sbs) Advis Tpg | Insider | Sell | 1,300,000 | $25.97 | $33,761,000.00 | | |
| 7/10/2014 | Group Holdings (Sbs) Advis Tpg | Major Shareholder | Sell | 1,000,000 | $25.17 | $25,170,000.00 | | |
| 7/9/2014 | Group Holdings (Sbs) Advis Tpg | Major Shareholder | Sell | 500,000 | $25.05 | $12,525,000.00 | | |
| 5/22/2014 | Anand Mehra | Director | Sell | 323,932 | $16.00 | $5,182,912.00 | | |
| 5/22/2014 | Iv L.P. Acp | Major Shareholder | Sell | 300,000 | $16.00 | $4,800,000.00 | | |
| 5/16/2014 | Gerald Cagle | Director | Buy | 1,854 | $15.07 | $27,939.78 | 1,854 | |
| 10/30/2013 | Brian Levy | Insider | Buy | 6,000 | $10.00 | $60,000.00 | | |
| 10/30/2013 | Iv L.P. Acp | Major Shareholder | Buy | 110,000 | $10.00 | $1,100,000.00 | | |
| 10/30/2013 | Richard J Rubino | CFO | Buy | 10,000 | $10.00 | $100,000.00 | | |
| 10/30/2013 | Thomas A Mitro | COO | Buy | 5,000 | $10.00 | $50,000.00 | | |
| 10/30/2013 | Vicente Anido Jr | CEO | Buy | 28,000 | $10.00 | $280,000.00 | | |
| 10/25/2013 | Anand Mehra | Director | Buy | 285,000 | $10.00 | $2,850,000.00 | | |
| 10/25/2013 | Lifesciences Ii L.P. Clarus | Major Shareholder | Buy | 321,000 | $10.00 | $3,210,000.00 | | |
(Data available from 1/1/2013 forward)
Aerie Pharmaceuticals (NASDAQ AERI) News Headlines
| Source: |
|
Aerie Pharmaceuticals (NASDAQ:AERI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aerie Pharmaceuticals (NASDAQ:AERI) Income Statement, Balance Sheet and Cash Flow Statement
Aerie Pharmaceuticals (NASDAQ AERI) Stock Chart for Sunday, May, 27, 2018
Loading chart…
